Expert Interview
Discussing the future of Amarin, with recent Vascepa litigation & new data in the spotlight
Ticker(s): AMRNAn cardiologist with experience prescribing Vascepa.
Please tell us about your experience. How many patients with high triglycerides and high cholesterol do you treat?
Added By: slingshot_insightsHow much do you believe the recent FDA’s invalid due to obviousness ruling on Amarin’s patents for Vascepa will affect the prescriptions from now on?
Added By: slingshot_insightsWhat are some of the ex-U.S. potential barriers to generic competition?
Added By: slingshot_insightsConsidering generics are not yet approved and penalties for at-risk generic launches remain, how much do you feel Vascepa will keep its appeal to clinicians and patients?
Added By: slingshot_insightsIf Amarin were to enter into settlements with generic companies for Vascepa in the U.S., would that change your impression on the drug or the company in any meaningful way?
Added By: slingshot_insightsIn a recent data release, Serum EPA Levels were reported at 400% Increase and DHA levels showed a decrease of 2.9%, Following Administration of VASCEPA. Can you walk us through the importance of this data point?
Added By: slingshot_insightsWhat can you tell us related to the cost-effectiveness study? How much do patients have to pay, on average, and how would that change in the event of generic competition?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
